Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Gastric01: Rilvegostomig + T-DXd + FP vs Pembrolizumab + Trastuzumab + Chemo in 1L HER2+ Gastric Cancer
NCT06764875Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 28
01
Overview
A Phase 3 trial of rilvegostomig in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Mar 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06764875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764875.